Novavax 2023-2024 COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S.
This Emergency Use Authorization and CDC recommendation makes Novavax’s vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. Novavax
Read MoreThis Emergency Use Authorization and CDC recommendation makes Novavax’s vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. Novavax
Read MoreModified agreement also includes the development of an updated vaccine in fall 2023 GAITHERSBURG, Md., Feb. 13, 2023 /PRNewswire/ —
Read MoreGAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation
Read MoreGAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation
Read MoreGAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation
Read MoreGAITHERSBURG, Md., Dec. 14, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation
Read MoreThe Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary Novavax’ prototype
Read MoreGAITHERSBURG, Md., Oct. 19, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation
Read MoreHomologous boosting with the prototype Novavax COVID-19 vaccine induced robust antibody titers for Omicron BA.1, BA.2, and BA.5 Study 307
Read MoreNovavax’ vaccine is the first protein-based COVID-19 vaccine authorized in the U.S. Doses of the Novavax COVID-19 Vaccine, Adjuvanted are
Read More